Aplastic Anemia Market to Cross USD 300 Million by 2036 Amid Steady Reliance on Immunosuppressive Therapies and Emerging Cell-Based Approaches

DelveInsight's "Aplastic Anemia Market Insights, Epidemiology, and Market Forecast 2036" report provides comprehensive insights into the Aplastic Anemia market size, historical and forecasted epidemiology, current and emerging treatment landscape, and market opportunity across the 7MM, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Download DelveInsight's comprehensive Aplastic Anemia Market Report to explore emerging therapies, key players, and future treatment landscapes: https://www.delveinsight.com/report-store/aplastic-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Key Takeaways from the Aplastic Anemia Market Report
• The global Aplastic Anemia Market was valued at approximately USD 300 million in 2025 and is projected to grow at a CAGR of ~2%, crossing USD 300 million by 2036.
• Among the 7MM, the United States held the largest Aplastic Anemia Market share in 2025, while Japan accounted for the highest number of total incident cases, with approximately 850 cases in 2025.
• The total incident cases of Aplastic Anemia in the 7MM were approximately 2,600 in 2025.
• Severe and very severe aplastic anemia (SAA) patients contribute roughly 65%-80% of the total aplastic anemia patient population, with the United States recording the highest severity-specific cases at approximately 430 in 2025.
• In December 2025, the US FDA approved OMISIRGE (omidubicel-onlv), the first cellular therapy for severe aplastic anemia (SAA), developed by Ayrmid (Gamida Cell).
• In April 2025, Cellenkos announced that the US FDA had granted Orphan Drug Designation to its novel cell therapy product, CK0801.
• Regeneron announced in 2025 that it had discontinued the study of REGN7257 in Aplastic Anemia.
• Leading Aplastic Anemia Companies include Ayrmid (Gamida Cell), Teva Pharmaceuticals, Kyowa Kirin, Cellenkos, and others.

Access DelveInsight's in-depth Aplastic Anemia Market Analysis for a closer look at promising breakthroughs: https://www.delveinsight.com/report-store/aplastic-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Aplastic Anemia Market Report Scope
The Aplastic Anemia Market Report provides an assessment of current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM market size from 2022 to 2036. The report also covers treatment algorithms, market practices, unmet needs, and key opportunities shaping the future market landscape.

Aplastic Anemia Overview
Aplastic anemia is a rare and severe non-malignant disease characterized by autoimmune destruction of early hematopoietic cells, resulting in pancytopenia with a hypocellular bone marrow. Global incidence ranges from 0.7 to 7.4 cases per million inhabitants per year, with higher rates observed in Asia compared to Europe and the United States.
The disease is broadly classified into congenital and acquired types. Inherited variants are uncommon and include Fanconi anemia, dyskeratosis congenita, congenital pure red cell aplasia, and Shwachman-Diamond syndrome. Management approaches center on hematopoietic stem cell transplantation (HSCT) and anti-thymocyte globulin (ATG)-based immunosuppressive therapy (IST), with treatment selection guided by patient age, donor availability, and disease severity.
Despite advances in transplantation safety, outcomes in elderly patients remain suboptimal, with mortality rates of approximately 10-20% driven by graft-versus-host disease, infections, and other procedure-related toxicities.

Aplastic Anemia Emerging Drugs Profile

CK0801 - Cellenkos
CK0801 is a first-in-class, allogeneic, cord blood-derived T-regulatory cell product developed using Cellenkos' proprietary manufacturing platform, designed to overcome immune dysfunction by inhibiting key drivers of inflammation. The therapy contains robust regulatory T-cells derived from healthy donor cord blood units and has received Orphan Drug Designation from the US FDA. CK0801 is currently in Phase I clinical development.

Explore groundbreaking therapies and clinical trials in the Aplastic Anemia Market. Access DelveInsight's detailed report: https://www.delveinsight.com/report-store/aplastic-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

The Aplastic Anemia Market Report Provides Insights Into
• Detailed assessment of companies developing therapies for Aplastic Anemia, along with market size and share estimates by therapy.
• Evaluation of therapeutic candidates across marketed and Phase I stages of development.
• Analysis of targeted therapeutics, including HSCT-based cell therapies, thrombopoietin (TPO) receptor agonists, and T-regulatory cell products.
• Assessment of pipeline drugs based on development stage, route of administration, mechanism of action, and molecule type.
• Detailed analysis of collaborations, acquisitions and mergers, licensing agreements, and patent information shaping future market advancement.
• Comprehensive evaluation of marketed and emerging therapies and their potential market uptake.

Aplastic Anemia Companies
Key companies involved in the Aplastic Anemia Market include:
• Ayrmid (Gamida Cell)
• Teva Pharmaceuticals
• Kyowa Kirin
• Cellenkos
• Others

Aplastic Anemia Market - Route of Administration
The Aplastic Anemia Market Report provides a therapeutic assessment of pipeline and marketed drugs by route of administration.
• Oral
• Intravenous

Aplastic Anemia Market - Molecule Types
Aplastic Anemia products are categorized into the following molecule types:
• Thrombopoietin (TPO) Receptor Agonist
• Cellular Therapy (Cord Blood-Derived HSCT Product)
• T-Regulatory Cell Product

Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments: https://www.delveinsight.com/report-store/aplastic-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Scope of the Aplastic Anemia Market Report
• Coverage: 7MM - United States, EU4, United Kingdom, and Japan
• Study Period: 2022-2036
• Forecast Period: 2026-2036
• Aplastic Anemia Companies: Ayrmid (Gamida Cell), Teva Pharmaceuticals, Kyowa Kirin, Cellenkos, and others
• Aplastic Anemia Therapies: OMISIRGE, ALVAIZ (eltrombopag choline), ROMIPLATE (romiplostim), CK0801, and others
• Aplastic Anemia Market CAGR: Approximately 2% during 2026-2036
• Therapeutic Assessment by Clinical Stage: Marketed and Phase I

Table of Contents
• Introduction
• Executive Summary
• Aplastic Anemia: Overview
• Epidemiology and Patient Burden Assessment
• Aplastic Anemia Current Treatment Practices
• Aplastic Anemia Marketed Drugs
• Aplastic Anemia Emerging Drugs
• Aplastic Anemia Pipeline Development Activities
• Aplastic Anemia Market Outlook and Drugs Uptake
• Aplastic Anemia Market Access and Reimbursement
• Latest KOL Views on Aplastic Anemia
• Aplastic Anemia Qualitative Analysis
• Aplastic Anemia Market Size and Forecast, 2022-2036
• Aplastic Anemia Key Companies
• Aplastic Anemia Market Drivers and Barriers
• Appendix

Contact Information
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: mmalhotra@delveinsight.com
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm providing high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, DelveInsight offers customized research solutions and actionable insights to clients worldwide.

This release was published on openPR.